Invega Hafyera received FDA approval on April 26, 2023 [1].
When is the earliest Invega Hafyera can be launched?
The launch date for Invega Hafyera is tied to patent protections. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for pharmaceuticals, which determine when generic or biosimilar versions can enter the market [2].
What is Invega Hafyera used to treat?
Invega Hafyera is a long-acting injectable antipsychotic used for the treatment of schizophrenia in adult patients [1].
How does Invega Hafyera work?
Invega Hafyera is a long-acting injectable formulation of paliperidone palmitate, which is a metabolite of risperidone. It is designed to release paliperidone palmitate gradually over time, providing sustained therapeutic levels [1].
What is the dosing schedule for Invega Hafyera?
Invega Hafyera is administered monthly, following an initial loading dose regimen [1].
What are the potential side effects of Invega Hafyera?
Common side effects associated with Invega Hafyera may include injection site reactions, weight gain, and headache. Serious side effects can occur, and patients should discuss these with their healthcare provider [1].
How does Invega Hafyera compare to other Invega formulations?
Invega Hafyera offers a monthly dosing schedule, differentiating it from other paliperidone palmitate formulations which may have different injection frequencies, such as every three months for Invega Trinza [1].
What is the patent situation for Invega Hafyera?
Information regarding the specific patents covering Invega Hafyera and their expiration dates is available through resources like DrugPatentWatch.com, which tracks patent lifecycles for drugs [2].
Who manufactures Invega Hafyera?
Invega Hafyera is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-full-text-2023
[2] https://drugpatentwatch.com/